/ADMA
ADMA Stock - ADMA Biologics, Inc.
Healthcare|BiotechnologyNASDAQ
$19.58+4.09%
+$0.77 (+4.09%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.75
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-52.5%upside
Target: $9.30
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADMA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$19.38 – $19.78
TARGET (TP)$9.30
STOP LOSS$18.01
RISK/REWARD1:-6.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.43
52W High$25.67
52W Low$13.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $426.45M | $258.21M | $154.08M | $80.94M | $42.22M |
| Gross Profit | $219.55M | $88.94M | $35.27M | $1.17M | $-19,071,643 |
| Gross Margin | 51.5% | 34.4% | 22.9% | 1.4% | -45.2% |
| Operating Income | $138.98M | $21.63M | $-39,365,000 | $-58,374,000 | $-64,914,877 |
| Net Income | $197.67M | $-28,239,000 | $-65,904,000 | $-71,648,000 | $-75,748,548 |
| Net Margin | 46.4% | -10.9% | -42.8% | -88.5% | -179.4% |
| EPS | $0.85 | $-0.13 | $-0.43 | $-0.61 | $-1.02 |
Company Overview
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
1
50%
Buy / Outperform
1
50%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↓ 74.5% Downside
Now
$5
Low
$5
Average
$5
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 19th 2023 | Raymond James | Resumed | Strong Buy | $5 |
| October 13th 2022 | Mizuho | Initiation | Buy | $5 |
Earnings History & Surprises
ADMABeat Rate
61%
Last 18 quarters
Avg Surprise
+44.9%
EPS vs Estimate
Beats / Misses
11/4
3 met exactly
Latest EPS
$0.16
Q4 2025
EPS Surprise History
Q1 24
+420.0%
$0.04vs$-0.01
Q2 24
+33.3%
$0.08vs$0.06
Q3 24
+62.5%
$0.13vs$0.08
Q4 24
+15.4%
$0.15vs$0.13
Q1 25
-6.7%
$0.14vs$0.15
Q2 25
-12.5%
$0.14vs$0.16
Q3 25
+7.1%
$0.15vs$0.14
Q4 25
0.0%
$0.16vs$0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | — | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.16 | $0.16 | 0.0% | = MET |
Q3 2025 | Aug 6, 2025 | $0.14 | $0.15 | +7.1% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.16 | $0.14 | -12.5% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $0.15 | $0.14 | -6.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.13 | $0.15 | +15.4% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.08 | $0.13 | +62.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.06 | $0.08 | +33.3% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.01 | $0.04 | +420.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.00 | $0.01 | +233.3% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.02 | $-0.02 | -20.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.08 | $-0.08 | 0.0% | = MET |
Q3 2022 | Aug 10, 2022 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.08 | $-0.10 | -25.0% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.15 | $-0.15 | 0.0% | = MET |
Latest News
UPDATE: ADMA Biologics Q3 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $134.224M Beat $130.533M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 11:18 PM
ADMA Biologics FY2026 Revenue expected to be at least $630.000M vs $637.727M Est
📉 NegativeBenzinga•Nov 5, 2025, 09:18 PM
ADMA Biologics FY2025 Revenue expected to be at least $510.000M vs $506.202M Est
📈 PositiveBenzinga•Nov 5, 2025, 09:14 PM
ADMA Biologics Q3 EPS $0.15, Inline, Sales $134.224M Beat $130.533M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:12 PM
ADMA Biologics Option Alert: Nov 21 $15 Calls Sweep (8) near the Ask: 2000 @ $1.076 vs 372 OI; Earnings 11/6 After Close [est] Ref=$14.225
📈 PositiveBenzinga•Oct 8, 2025, 05:18 PM
Frequently Asked Questions about ADMA
What is ADMA's current stock price?
ADMA Biologics, Inc. (ADMA) is currently trading at $19.58 per share. The stock has moved +4.09% today.
What is the analyst price target for ADMA?
The average analyst price target for ADMA is $9.30, based on 1 analyst.
What sector is ADMA Biologics, Inc. in?
ADMA Biologics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ADMA's market cap?
ADMA Biologics, Inc. has a market capitalization of $4.66 billion, making it a mid-cap company.
Does ADMA pay dividends?
No, ADMA Biologics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
BLTE
Belite Bio, Inc
$156.00
Mkt Cap: $5.4B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
MIRM
Mirum Pharmaceuticals, Inc.
$77.74
Mkt Cap: $3.8B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
TLX
Telix Pharmaceuticals Limited
$7.80
Mkt Cap: $2.6B
Explore stocks similar to ADMA for comparison